

Ryosuke Kuribayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5639794/publications.pdf>

Version: 2024-02-01

11
papers

88
citations

1683354

5
h-index

1372195

10
g-index

12
all docs

12
docs citations

12
times ranked

143
citing authors

#	ARTICLE	IF	CITATIONS
1	Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects. AAPS Journal, 2015, 17, 1312-1316.	2.2	23
2	Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan. Journal of Pharmaceutical Sciences, 2016, 105, 2270-2277.	1.6	16
3	Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union. Clinical Pharmacokinetics, 2017, 56, 225-233.	1.6	15
4	Current Japanese Regulatory Systems for Generics and Biosimilars. Journal of Pharmaceutical Sciences, 2018, 107, 785-787.	1.6	9
5	A Survey of the Regulatory Requirements for the Acceptance of Foreign Comparator Products by Participating Regulators and Organizations of the International Generic Drug Regulators Programme. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 28-36.	0.9	8
6	Comparison of Generic Drug Reviews for Marketing Authorization between Japan and Canada. Drugs in R and D, 2017, 17, 371-379.	1.1	5
7	Current Understanding of the Equivalence Evaluations for In Vitro Tests on Generic Dry Powder Inhaler Drug Products in Japan. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 743-745.	0.6	4
8	Modernization and Strengthening of Bioequivalence Guidelines in Japan. Clinical Pharmacokinetics, 2021, 60, 145-151.	1.6	3
9	First approval of generic dry powder inhaler drug products in Japan. Drug Delivery and Translational Research, 2020, 10, 1517-1519.	3.0	2
10	Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan. European Journal of Drug Metabolism and Pharmacokinetics, 2020, 45, 697-702.	0.6	2
11	Generic Drug Product Development in Japan: Regulatory Updates During 2014-2019 and the Future. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 711-719.	0.6	1